News | August 29, 2025
Lilly's oral GLP-1 orforglipron succeeds in Phase 3 trial
Triggering global regulatory submissions this year for the treatment of obesity
Triggering global regulatory submissions this year for the treatment of obesity
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Rivaroxaban is used to treat venous thromboembolism
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
Subscribe To Our Newsletter & Stay Updated
